| Document | Amneal Pharmaceuticals Second Quarter 2026 Earnings Results |
| 2026-07-29 | Earnings deck | Amneal Pharmaceuticals Second Quarter 2026 Earnings Presentation |
| 2026-07-17 | Press release | Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations |
| 2026-07-09 | Press release | Amneal to Report Second Quarter 2026 Results on July 30, 2026 |
| 2026-07-08 | Press release | Amneal and Adalvo Announce FDA Acceptance for Review of Two U.S. ANDAs for Generic Tirzepatide Autoinjector |
| 2026-07-01 | Press release | Amneal’s New U.S. Sterile Manufacturing Facility Selected for FDA PreCheck Pilot Program |
| 2026-06-05 | Press release | Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of C |
| 2026-06-04 | Press release | Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution |
| 2026-06-01 | Press release | Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026 |
| Press release | Amneal Reports First Quarter 2026 Financial Results |
| 2026-04-22 | Press release | Download PDF file, (opens in new window) |
| 2026-04-22 | Press release | Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter |
| 2026-04-20 | Press release | Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including |
| 2026-04-14 | Press release | Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S. |
| 2026-04-09 | Press release | Amneal Launches Bimatoprost Ophthalmic Solution, 0.01% |
| 2026-04-07 | Press release | Amneal to Report First Quarter 2026 Results on May 1, 2026 |
| 2026-04-07 | Press release | Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month |
| 2026-03-24 | Press release | Amneal Pharmaceuticals LLC Issues Voluntary Nationwide Recall of Magnesium Sulfate in Water for Injection, USP 4 g/100mL |
| 2026-03-05 | Press release | Amneal to Participate in Upcoming Investor Conference |
| Document | Amneal Pharmaceuticals Fourth Quarter 2025 Earnings Results |
| 2026-02-26 | Presentation | View Presentation (PDF1.11 MB)(opens in new window) |
| 2026-01-28 | Press release | Amneal Pharmaceuticals Added to S&P SmallCap 600® Index |
| 2026-01-27 | Press release | Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026 |
| 2026-01-12 | Press release | Amneal Unveils Bold New Brand to Reimagine What’s Possible in Making Medicine Accessible for All |
| 2025-12-22 | Press release | Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA® |
| 2025-12-09 | Press release | Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals |
| 2025-12-05 | Press release | Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease |
| 2025-12-02 | Press release | Amneal to Participate in Upcoming Investor Conferences |
| 2025-12-02 | Press release | Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol |
| 2025-12-01 | Press release | Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05% |
| 2025-11-13 | Press release | Amneal Receives U.S. FDA Approval for Iohexol Injection |
| 2025-11-04 | Press release | Amneal Named a 2026 BioSpace Best Places to Work Winner |
| Document | Amneal Pharmaceuticals Third Quarter 2025 Earnings Results |
| 2025-10-30 | Presentation | https://s22.q4cdn.com/186279204/files/doc_downloads/2026/05/Amneal-Investor-page-May-2026.pdf |
| 2025-10-29 | Earnings deck | Amneal Pharmaceuticals Third Quarter 2025 Earnings Presentation |
| 2025-10-29 | Press release | Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol |
| 2025-10-27 | Press release | Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster |
| 2025-09-30 | Press release | Amneal to Report Third Quarter 2025 Results on October 30, 2025 |
| 2025-09-26 | Press release | Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab) |
| 2025-09-23 | Press release | Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01% |